UK pharma giant GlaxoSmithKline (LSE: GSK), already subject to allegations of bribery of doctors and hospitals in China, declared late yesterday that it is now under investigation by the UK's Serious Fraud Office (SFO).
In a terse statement without giving specifics, GSK stated that it has (on May 27) “been informed by the UK’s Serious Fraud Office that it has opened a formal criminal investigation into the group’s commercial practices. GSK is committed to operating its business to the highest ethical standards and will continue to cooperate fully with the SFO.”
Similar allegations in other countries
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze